Effectiveness of rituximab in neuromyelitis optica: a meta-analysis

Effectiveness of rituximab in neuromyelitis optica: a meta-analysis

Abstract Background Neuromyelitis optica (NMO) is a severe inflammatory autoimmune disorder of the central nervous system and often results in paralysis or blindness. Rituximab (RTX) is a mouse–human chimeric monoclonal antibody specific for the CD20 antigen on B lymphocytes and used to treat many a...

Full description

Bibliographic Details
Main Authors: Fulin Gao, Bingyan Chai, Cheng Gu, Ruipeng Wu, Tong Dong, Yuping Yao, Yi Zhang
Format: Article
Language:English
Published: BMC 2019-03-01
Series:BMC Neurology
Subjects:
Neuromyelitis optica
Rituximab
Meta-analysis
Aquaporin-4 autoantibody
Annualized relapse rate
Expanded disability status scale
Online Access:http://link.springer.com/article/10.1186/s12883-019-1261-2

Internet

http://link.springer.com/article/10.1186/s12883-019-1261-2

Similar Items